HIMA's Candace Littell.
This article was originally published in The Gray Sheet
Executive Summary
Littell joins Health Industry Manufacturers Association as senior health policy advisor. Prior to joining HIMA, Littell ran a Washington, D.C. consulting firm, CL Littell & Associates, which focused on payment issues. Littell went into consulting after leaving as executive director of the Health Care Technology Institute at the end of 1994. HCTI, which later closed, was formed by HIMA to study the impact of medical technology on health care costs and productivity. At HIMA, Littell will be working with Ted Mannen, executive VP, health systems, and Greg Raab, who is shifting from FDA reform work as VP, government affairs, to reimbursement issues as senior health affairs advisor...
You may also be interested in...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.